*November 2024* In this video, Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, discuss the next steps for biomarker testing in NSCLC. Watch here.
laurabbook@gmail.comDecember 21, 2024
Recent News & Research
*November 2024* Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie, discusses de novo vs acquired resistance alterations in HER2-positive non–small cell lung cancer (NSCLC). In HER2-positive NSCLC, alterations can be broadly categorized as either de novo mutations or acquired resistance mutations, Girard begins. De novo mutations…
laurabbook@gmail.comDecember 21, 2024
*November 2024* Key Takeaways Datopotamab deruxtecan targets EGFR-mutated advanced NSCLC, showing promising response and disease control rates in the TROPION-Lung05 trial. The TROPION-Lung01 trial showed non-significant overall survival improvement, leading to the withdrawal of the BLA for nonsquamous NSCLC. Safety data indicated that all patients experienced treatment-emergent adverse effects, with…
laurabbook@gmail.comDecember 21, 2024
*October 2024* Abstract Purpose This multicenter, randomized, phase III clinical trial (Northern Radiation Oncology Group of China-002) focused on patients with oligo-organ metastatic non–small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations. We aimed to investigate whether first-line concurrent thoracic radiotherapy (TRT) and EGFR-tyrosine kinase inhibitors…
laurabbook@gmail.comDecember 21, 2024
In the US, young and middle-aged women are being diagnosed with lung cancer at higher rates than men
*November 2024* Susan Wojcicki, the late CEO of YouTube, had a message for the world just weeks before she passed. “Although lung cancer overall is decreasing because of declines in tobacco use, lung cancer among people who have never smoked has been rising significantly,” Wojcicki wrote in a YouTube blog that was posted…
laurabbook@gmail.comDecember 21, 2024
*November 2024* Leigh Durant’s experience as the lung cancer caregiver for her mother, Alice Hughes, began in April 2024, when Alice told Leigh she just didn’t feel like herself. Leigh said, “She’s always been very aware of her body, her physical state.” Because of that, even though Alice had suffered…
laurabbook@gmail.comDecember 17, 2024
*November 2024* LCRF’s 2024 Scientific Symposium was held November 4 as part of their Lung Cancer Awareness Month activities. Joining the record-breaking group online were event lead and moderator, Kathryn O’Donnell, PhD; chat moderator, Isabel Preeshagul, DO, MBS; and speakers Brendon M. Stiles, MD; Colleen Conner Ziegler; Mark Awad, MD,…
laurabbook@gmail.comDecember 17, 2024
*October 2024* Abstract Purpose This multicenter, randomized, phase III clinical trial (Northern Radiation Oncology Group of China-002) focused on patients with oligo-organ metastatic non–small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations. We aimed to investigate whether first-line concurrent thoracic radiotherapy (TRT) and EGFR-tyrosine kinase inhibitors…
laurabbook@gmail.comDecember 17, 2024
*October 2024* In a new study published in Nature Medicine UHN researchers have identified specific DNA changes that can predict a patient’s risk of cancer spreading to the brain, offering new approaches to managing patients and improving health outcomes. The spread of cancer to the brain, known as brain metastasis, significantly reduces…
laurabbook@gmail.comDecember 17, 2024
*November 2024* Highlights •EGFR-TKIs have improved outcomes for patients with EGFR-mutant NSCLC. •Acquired resistance occurs through complex and multifaceted mechanisms. •C797S mutation emerges in 6–12 % of patients treated with first-line osimertinib. •Fourth-generation EGFR-TKIs are active against common and resistance EGFR mutations. •Phase 1/2 clinical trials are ongoing, with promising activity…
laurabbook@gmail.comDecember 17, 2024
